Increased Plasma S100β Level in Patients with Major Depressive Disorder
Yuan Fang,Shifu Xiao,Sheng‐Yu Zhang,Qi Qiu,Tao Wang,Xia Li
DOI: https://doi.org/10.1111/cns.12517
2016-01-01
CNS Neuroscience & Therapeutics
Abstract:CNS Neuroscience & TherapeuticsVolume 22, Issue 3 p. 248-250 Letter to the EditorOpen Access Increased Plasma S100β Level in Patients with Major Depressive Disorder Yuan Fang, Yuan Fang Alzheimer's Disease and Related Disorders Center, Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorShi-Fu Xiao, Shi-Fu Xiao Alzheimer's Disease and Related Disorders Center, Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorSheng-Yu Zhang, Sheng-Yu Zhang Alzheimer's Disease and Related Disorders Center, Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorQi Qiu, Qi Qiu Alzheimer's Disease and Related Disorders Center, Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorTao Wang, Tao Wang Alzheimer's Disease and Related Disorders Center, Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorXia Li, Corresponding Author Xia Li Alzheimer's Disease and Related Disorders Center, Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China Correspondence X. Li, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 Wan Ping Nan Road, Shanghai 200030, China. Tel.: +86-21-6438-7250; Fax: +86-21-6438-7986; E-mail: ja_1023@hotmail.comSearch for more papers by this author Yuan Fang, Yuan Fang Alzheimer's Disease and Related Disorders Center, Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorShi-Fu Xiao, Shi-Fu Xiao Alzheimer's Disease and Related Disorders Center, Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorSheng-Yu Zhang, Sheng-Yu Zhang Alzheimer's Disease and Related Disorders Center, Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorQi Qiu, Qi Qiu Alzheimer's Disease and Related Disorders Center, Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorTao Wang, Tao Wang Alzheimer's Disease and Related Disorders Center, Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorXia Li, Corresponding Author Xia Li Alzheimer's Disease and Related Disorders Center, Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China Correspondence X. Li, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 Wan Ping Nan Road, Shanghai 200030, China. Tel.: +86-21-6438-7250; Fax: +86-21-6438-7986; E-mail: ja_1023@hotmail.comSearch for more papers by this author First published: 05 February 2016 https://doi.org/10.1111/cns.12517Citations: 11AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat To this day, the diagnosis of major depressive disorder (MDD) still depends on the presentation of clinical symptoms. Therefore, there is a great need for biomarkers that can improve the diagnosis and prediction of treatment response, which in turn can reduce patients' suffering and treatment cost 1. S100 calcium-binding protein β (S100β) normally exists in the astrocytes and glial cells of the central nervous system. S100β can penetrate the brain–blood barrier, which makes it possible to detect the central concentration by measuring its plasma level 2. Recently, fluctuations in serum levels of S100β in depressed patients were reported and aroused interest in the glial pathology of MDD, although the specific mechanism or relevant factors, such as antidepressant usage or age, remain undetermined 3, 4. Animal research conducted by Baudry indicated that with long-term selective serotonin reuptake inhibitor (SSRI) treatment, S100β protein was released in the raphe nucleus brain region in mice and then the 5-hydroxytryptamine (serotonin, 5-HT) concentration in the synaptic cleft of the locus coeruleus was determined 5. But evidence from human studies to support such a conclusion is absent. Our published research has shown that the 5-HT levels in platelets decrease in chronic unpredictable mild stimulation (CUMS) rats and patients treated using the SSRI citalopram 6. In this study, we will further illustrate S100β and its relation with 5-HT in the blood of patients with MDD, to provide basis for further research establishing a biological marker for depression. A case–control design was used for this study. Participants included forty-five patients with treatment-naïve MDD who had not taken antidepressants (drug-naïve group, DN group), thirty-two MDD patients treated with citalopram for at least 6 weeks (citalopram-treated group, CPT group), and thirty-two healthy controls. Further details of this study including participant screening, informed consent process, and overall study process are reported in our previously published article 6. The mean ages of the DN, CPT, and control groups were 39.6(±13.2), 44.4(±14.4), and 44.3(±9.4) years, respectively. Female participants made up 57.8%, 71.9%, and 71.9% of the DN, CPT, and control groups, respectively. There was no significant difference between the three groups in gender or age. All participants were evaluated by a psychiatrist using the Hamilton Depression Scale (HAMD, 17 items) and Hamilton Anxiety Scale (HAMA). The mean HAMD-17 scores of the DN, CPT and control groups were 22.0(±3.90), 8.2(±4.67), and 1.4(±1.32), while the mean HAMA scores were 13.9(±5.81), 6.3(±4.90), and (1.5 ± 1.01), respectively. The statistically significant difference in mean HAMD-17 and HAMA scores among the three groups (p < 0.01) was reported in our previous article 6. The s100β (Human) enzyme-linked immunosorbent assay (ELISA) kit (Abnova Corporation, Jhongli City, Taiwan) was used to detect S100β protein levels in the plasma. As shown in Figure 1, the mean s100β plasma levels (unit: pg/mL) of the DN, CPT, and control groups were 21.01(±7.69), 22.12(±9.09), and 16.80(±4.99), respectively. Using the Kruskal–Wallis test, a significant difference was found among the groups in mean s100β plasma levels (F = 9.41, P = 0.009). Compared with healthy controls, patients with MDD (whether or not they had received citalopram) had elevated s100β plasma protein levels (P < 0.05). There was no significant difference between the DN group and CPT group (P > 0.05) in mean s100β plasma levels. Spearman correlational analysis for s100β plasma levels and HAMD or HAMA scores was conducted for the entire MDD sample. Results showed that there was no correlation between s100β plasma protein levels and HAMD or HAMA scores (see Figure 2A & B). The results remained unchanged even after citalopram-treated patients were excluded (see Figure 2C & D). Figure 1Open in figure viewerPowerPoint s100β plasma protein levels increased in MDD patients with or without antidepressant treatment. *p < 0.05, compared with healthy controls, MDD participants in the drug naïve group (DN group) or in the citalopram treatment group (CPT group) had elevated s100β plasma protein levels. ns: p > 0.05, no significant difference between the DN group and CPT group. Figure 2Open in figure viewerPowerPoint Plasma s100β levels were not correlated to HAMD and HAMA scores in MDD patients. A, B: All MDD patients including Drug-Naïve and citalopram treated participants (n = 77); C, D: only drug-naïve depressed patients (n = 45). Although it is consistently shown that serum s100β levels are higher in people who suffer from depression, the evidence varies in many respects. Some studies show that plasma s100β levels are higher in patients with melancholic MDD, whereas serum s100β levels in patients with nonmelancholic MDD are similar to those of normal controls7. Other studies show that s100β plasma levels are not related to the severity of depressive symptoms, but higher levels can predict better treatment response in MDD 8, 9. Our study showed that plasma s100β levels were higher in patients with MDD, but were not correlated with symptom severity and did not normalize with the SSRI treatment. Among drug-naïve patients, we followed fourteen of them who took citalopram for 6 weeks. The s100β level did not change (20.76 ± 6.69 pg/mL vs. 20.73 ± 7.53 pg/mL) with the clinical improvement, so we were unable to conclude that s100β could predict treatment effect from antidepressants. To our knowledge, serum s100β is well accepted as a sensitive biomarker for cerebral damage 10. Does the increased plasma s100β levels in MDD indicate minor cerebral damage? There is a hypothesis that the occurrence of MDD is closely related to neuroplasticity. The high plasma s100β protein levels in MDD group may indicate neurotoxicity in patients' brains and the neuroplasticity rebuilding actions. This question requires further investigation to answer properly. It has been reported that s100β, SSRIs, and the 5-HT system affect each other in the brain 5. We measured 5-HT platelet levels with high-performance liquid chromatography (details are in our previous publication 6). Using spearman correlational analysis, our results showed no correlation between plasma S100b and platelet 5-HT levels (r = −0.156, P = 0.105) among the participants. We inferred that the 5-HT system in blood has few effects on plasma s100β. In conclusion, we deduced that plasma s100β levels could be a state marker for MDD, but the increased level would not be changed by the SSRI treatment or blood 5-HT level. Further research should be carried out to clarify this mechanism. Acknowledgment This work was supported by grants from National Natural Science Foundation of China (No. 81101007) and the Shanghai Science & Technology Committee (No. 15411961400). Conflict of interest The authors declare no conflict of interest. References 1Bondy B, Buettner A, Zill P. Genetics of suicide. Mol Psychiatry 2006; 11: 336– 351. 2Beaudeux JL, Laribi S. S100B protein serum level as a biomarker of minor head injury. Ann Biol Clin (Paris) 2013; 71: 71– 78. 3Polyakova M, Sander C, Arelin K, et al. First evidence for glial pathology in late life minor depression: S100B is increased in males with minor depression. Front Cell Neurosci 2015; 9: 406. 4Schroeter ML, Steiner J, Mueller K. Glial pathology is modified by age in mood disorders–a systematic meta-analysis of serum S100B in vivo studies. J Affect Disord 2011; 134: 32– 38. 5Baudry A, Mouillet-Richard S, Schneider B, et al. miR-16 targets the serotonin transporter: A new facet for adaptive responses to antidepressants. Science 2010; 329: 1537– 1541. 6Li X, Fan Y, Xiao S, et al. Decreased platelet 5-hydroxytryptamin (5-HT) levels: A response to antidepressants. J Affect Disord 2015; 187: 84– 90. 7Rothermundt M, Arolt V, Wiesmann M, et al. S-100B is increased in melancholic but not in non-melancholic major depression. J Affect Disord 2001; 66: 89– 93. 8Arolt V, Peters M, Erfurth A, et al. S100B and response to treatment in major depression: A pilot study. Eur Neuropsychopharmacol 2003; 13: 235– 239. 9Ambree O, Bergink V, Grosse L, et al. S100B serum levels predict treatment response in patients with melancholic depression. Int J Neuropsychopharmacol 2015; doi: 10.1093/ijnp/pyv103. [Epub ahead of print]. 10Yuan SM. S100 and S100beta: Biomarkers of cerebral damage in cardiac surgery with or without the use of cardiopulmonary bypass. Rev Bras Cir Cardiovasc 2014; 29: 630– 641. Citing Literature Volume22, Issue3March 2016Pages 248-250 FiguresReferencesRelatedInformation